

# MINI PROGRAMME

THE INTERNATIONAL LIVER CONGRESS™

APRIL 10 - 14, VIENNA, AUSTRIA



#### Registration area – Foyer D

Membership fast-track, self-registration lanes, help desk, accommodation desk. congress material, congress app

Tuesday 09 April 16:00-19:00 Wednesday 10 to Saturday 13 April 07:00-19:00 Sunday 14 April 07:00-14:00

Executive lounge, faculty registration & speakers' ready room are located on 1st floor – same opening hours as registration area.

#### Cloakroom - Hall D

You will find the cloakroom by turning left towards Hall D from the registration area.

Wednesday 10 to Saturday 13 April 07:00-20:00 Sunday 14 April 07:00-14:00

#### **Exhibition, EASL community hub &** poster area - Hall B

Thursday 11 April 09:00\*-18:30 Friday 12 and Saturday 13 April 09:00\*-17:00

#### Wi-Fi internet connection

Network: ILC2019 Password: No password necessary



**DOWNLOAD THE ILC 2019 CONGRESS APP** 





34 **CME** Credits

#### The International Liver Congress (TM). Vienna. Austria. 10/04/2019-14/04/2019

has been granted 34 European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®).

#### What's your colour?

Follow the colour codes and pictogrammes throughout the programme to find sessions of interest to you.

#### **Specialties**













#### **Fields**

















#### Additional icons of interest

















<sup>\*</sup> Exhibitors and poster presenters have a special access as of 08:00.


# Wednesday 10 April 2019

08:00-08:30	RESEARCH THINK TANK		08:00-08:30
	Lehar 3 Factors aggravating portal hypertension	SKILLS IN HEPATOLOGY	
08:30-09:00	■ Lehar 1 EASL Regenerative Hepatology	Hepatology Arena Liver tumour board	08:30-09:00
	Strauss 3 Autoimmune and cholestatic liver diseases	a nopulating y manua ziron tamban saara	
09:00-09:30	Strauss 1-2 Chronic liver failure		09:00-09:30
09:30-10:00	Hall C1 Liver tumours	Coffee break	09:30-10:00
	Main Plenary NAFLD		
10:00-10:30	Lehar 4 Alcoholic liver disease Hall C3 Viral Hepatitis: vaccines and prison		10:00-10:30
	Hall C2 Hepatitis B cure	SKILLS IN HEPATOLOGY  Hepatology Arena Vascular liver disease board	
10:30-11:00	Lehar 2 Addressing drug user health to achieve HCV elimination	nepatology Arena vascular liver disease board	10:30-11:00
11:00-11:30	Lenal 2 Addressing drug user health to achieve flow eminimation		11:00-11:30
		I	
11:30-12:00			11:30-12:00
12:00-12:30	POSTGRADUATE COURSE  Main Plenary End stage liver disease	BASIC SCIENCE SEMINAR  Hall C3 Liver immunology and immunotherapy	12:00-12:30
12:30-13:00	Diagnosis of cirrhosis and portal hypertension: non-invasive or invasive tests?	Liver immunology	12:30-13:00
13:00-13:30			13:00-13:30
13:30-14:00	Lunch	Lunch \ \	13:30-14:00
14:00-14:30	POSTGRADUATE COURSE	BASIC SCIENCE SEMINAR	14:00-14:30
14:30-15:00	Main Plenary End stage liver disease	Hall C3 Liver immunology and immunotherapy	14:30-15:00
15:00-15:30	Bleeding and thrombosis	From discovery to therapy	15:00-15:30
15:30-16:00	Coffee break 🖐	Coffee break 🖐	15:30-16:00
16:00-16:30	POSTGRADUATE COURSE	BASIC SCIENCE SEMINAR	16:00-16:30
16:30-17:00	Main Plenary End stage liver disease	Hall C3 Liver immunology and immunotherapy	16:30-17:00
17:00-17:30	Cirrhosis and comorbidities	Liver inflammation and immune-oncology	17:00-17:30
17:30-18:00			17:30-18:00
18:00-18:30		OVILLO LEADUNIO OFFITRE	18:00-18:30
18:30-19:00	INDUSTRY SYMPOSIA	SKILLS LEARNING CENTRE  SLC 1 US simulators	18:30-19:00
19:00-19:30		Vascular liver disease and focal liver lesion	19:00-19:30
15.00-15.30			19.00-19:30

# Thursday 11 April 2019

07:30-08:00				SKILLS LEARNING CENTRE			07:30-08:00
08:00-08:30				SLC 1 US simulators: Vascular	liver disease and focal li	ver lesion	08:00-08:30
08:30-09:00	POSTGRADUATE COURSE  Main Plenary	BASIC SCIENCE SEMINAR Hall C3 Liver immunology and		MEET THE EXPERTS  Stolz 2 Wilson's disease			08:30-09:00
09:00-09:30	End stage liver disease  Managing bacterial infections and impaired renal function	immunotherapy Exploiting adaptive and innate immune mechanisms		Storz wilson's disease.  Stolz 1 is screening for HCC recurrence after liver transplantation. Do we need to screening after liver transplantation?			09:00-09:30
09:30-10:00			EILF SYMPOSIUM	MEET THE EVERTO			09:30-10:00
10:00-10:30	Coffee	break 🖢	■ Lehar 4 Liver Disease in Africa	MEET THE EXPERTS  Stolz 1 Exercise or diet – which is best for NAFLD  Stolz 2 Hepatitis C: What are the remaining difficult to treat patients and how to manage them?		ORAL ePOSTER  POSTER TOUR	10:00-10:30
10:30-11:00	POSTGRADUATE COURSE	BASIC SCIENCE SEMINAR		MEET THE EXPERTS	and the street in OLT		10:30-11:00
11:00-11:30	Main Plenary End stage liver disease	Hall C3 Liver immunology and immunotherapy		Stolz 1 Preventing long-term co Stolz 2 JHEP reports – Meet th			11:00-11:30
11:30-12:00	HE and ACLF in end-stage liver disease	Disease applications: Viral hepatitis and cancer, cholestasis and fatty liver disease				ELPA SYMPOSIUM 2019 NAFLD AND NASH FROM PATIENT PERSPECTIVE	11:30-12:00
12:00-12:30	TRANSLATIONAL STATE OF THE ART LECTURE Main Plenary Cell therapy in advanced liver disease	Hall C1 EASL Public Health Session: Influencing food and alcohol policy to Hall C2 Data management in registr Lehar 2 EASL Fellowship presentati	ies ons	MEET THE EXPERTS  Stolz 2 Animal models of liver disease Stolz 1 How to decide for resection versus other	ORAL ePOSTER POSTER TOUR	Strauss 1-2 What are the patient problems?	12:00-12:30
12:30-13:00		Lehar 3 Gender related topics in He EASL-ESCMID SYMPOSIUM	patology	therapies in HCC?			12:30-13:00
13:00-13:30	Lunch #1	Strauss 3 New diagnostic markers i EASL-CDC SYMPOSIUM Lehar 4 Best Practices in HCV Elimi PROS & CONS SESSION Hepatology Arena NASH does not al history – only fibrosis does	nation				13:00-13:30
13:30-14:00							13:30-14:00
14:00-14:30	Main Plenary GENERAL SESSION I AND OP	ENING CEREMONY					14:00-14:30
15:00-15:30							15:00-15:30
15:30-16:00		ORAL ePOSTER			POSTER TOUR		15:30-16:00
16:00-16:30	PARALLEL SESSIONS			MEET THE EXPERTS			16:00-16:30
16:30-17:00	Lehar 1 Liver disease immunol Lehar 2 Mechanism of regener	ation response to injury		Stolz 2 Artificial intelligence in the applications?  Stolz 1 Local therapies in HCC			16:30-17:00
17:00-17:30	Hall C2 Autoimmune and chole Hall C3 Portal Hypertension –	stasis I Refining risk stratification and therapy				oncology from 2019 to 2025  Strauss 3 Cascade of care	17:00-17:30
17:30-18:00	Lehar 3 Liver tumours — Experimental  Hall C1 NAFLD Pathophysiology — Target identification  Strauss 1-2 NAFLD — Clinical burden natural history  Main Plenary Hepatitis B/D/E — Clinical aspects			MEET THE EXPERTS Stolz 1 Renal dysfunction in th Stolz 2 How to manage the chr		towards elimination of VH Lehar 4 Launch of EILF centre of excellence in VH elimination in Georgia	17:30-18:00
18:00-18:30							18:00-18:30
18:30-19:00				SKILLS LEARNING CENTRE		• In the state of	18:30-19:00
19:00-19:15	INDUCTRY OVERDOOLS			SLC 1 Diagnostic ultrasound an elastography in hepatology	nd SLC	2 Invasive diagnostics methods	19:00-19:15
19:15-19:30	INDUSTRY SYMPOSIA			SKILLS LEARNING CENTRE  SLC 1 Diagnostic ultrasound an	nd Eic	2 Invasive diagnostics methods	19:15-19:30
	30-20:00			m <b>3LU I</b> DIAUTUSTIC UITASOUTU AT	ru   🚾 SLU	▲ IIIVasive Uldullustius IIIetilluus	19:30-20:00

#### Friday 12 April 2019



# Daily programme at a glance (cont.)

# Friday 12 April 2019

14:00-14:30	SYMPOSIA  Lehar 3 Liver disease in pregnancy  Main Plenary Albumin therapy in advanced liver disease —	PROS & CONS SESSION Hepatology Arena			MEET THE EXPERTS	14:00-14:30
14:30-15:00	Main Plenary Albumin therapy in advanced liver disease – From plasma expander to pleiotropic agent  EASL-APASL SYMPOSIUM  Hall C3 Recognising and managing the lean NAFLD patient  EASL-ECDC SYMPOSIUM  Lehar 4 Using real world data to inform Hepatitis B and C  elimination strategies		NURSES AND ALLIED HEALTH PROFESSIONALS FORUM Lehar 2 Adding value – the role of specialist	HAIL C1 HOT TOPICS IN LIVER TRANSPLANTATION Part II Innovative strategies to increase the donor	Stolz 1 Hepatic encephalopathy Stolz Management of immuno- suppression in AIH	14:30-15:00
15:00-15:30	FUSION HEPATOLOGY AROUND THE WORLD  Strauss 1-2 HCC – Special consideration in HBV infection  EASL-ESMO SYMPOSIUM  Lehar 1 Multidisciplinary approach of Cholangiocarcinoma.  From Diagnosis to treatment according to patient profile	PROS & CONS SESSION Hepatology Arena Patients with immuntolerant HBeAq positive	liver nurses and Allied Health Professionals	l Health liver transplant, split		15:00-15:30
15:30-16:00	Coffee break	infection should/ should not be treated		ORAL ePOSTER	POSTER TOUR	15:30-16:00
16:00-16:30	Strauss 3 Autoimmune and cholestasis II  Hall C3 Cirrhosis - Clinical aspects  Lehar 4 Acute and acute-on-chronic liver failure – Translational aspects  Strauss 1-2 Liver cancer – From Prognosis to locoregional treatments  Main Plenary NAFLD – Clinical Therapy  Hall C2 Hepatitis B – Drug development		■ Hepatology	HAII C1 HOT TOPICS IN LIVER TRANSPLANTATION Part III Multidisciplinary peri-transplant management of advanced liver	MEET THE EXPERTS  Stolz 1 Cell therapy for liver	16:00-16:30
16:30-17:00			arena Critical reflection on landmark papers 2018 Lehar 1		disease  Stolz 2 Endoscopic versus surgical bariatric approaches as interventions for NAFLD	16:30-17:00
17:00-17:30			Complementarity of academia and industry in		MEET THE EXPERTS Stolz 1 Targeted therapies in	17:00-17:30
17:30-18:00			viral hepatitis elimination strategies	diseases: Critical care in transplantation	genetic errors of metabolism  Stolz 2 Management of symptoms of PBC	17:30-18:00
18:00-18:30						18:00-18:30
18:30-19:00			SKILLS LEARNING C		h hanatalagy	18:30-19:00
19:00-19:15	INDUSTRY SYMPOSIA		■ SLC 1 Diagnostic ultrasound and elastography in hepatology ■ SLC 2 Invasive diagnostics methods	inopatology	19:00-19:15	
19:15-19:30			SKILLS LEARNING C	ENTRE Itrasound and elastography in	ı henatology	19:15-19:30
19:30-20:00			SLC 2 Invasive diag			19:30-20:00

# Saturday 13 April 2019

08:00-08:30	PARALLEL SESSIONS				MEET TH	IE EXPERTS	08:00-08:30
08:30-09:00	Strauss 1-2 Non-invasive assessment of liver disease Strauss 3 Clinical developments in rare liver disease Lehar 3 Liver transplantation I		SOLVE THE CASE  Hepatology Arena NASH		transp	Kidney failure after liver lantation      When to use TIPS in cirrhosis	08:30-09:00
09:00-09:30	Hall C3 Cirrrhosis – Experimental aspects						09:00-09:30
09:30-09:45	Hall C2 Liver cancer – Systemic treatment and immunotherapy Hall C1 NAFLD – Preclinical pipeline Lehar 2 Gut-Liver Axis Lehar 4 Alcohol related liver disease Main Plenarry Hepatitis C – Treatment and resistance Lehar 1 Translational virology		I .	ontrast agents in the dia : When to stop NA thera		staging of liver tumours	09:30-09:45
09:45-10:00							09:45-10:00
10:00-10:30							10:00-10:30
10:30-11:00							10:30-11:00
11:00-11:15	Main Plenary GENERAL SESSION III AND AWARD CEREMONY II						11:00-11:15
11:15-11:30	GENERAL SESSION III AND AWARD CEREMONT II						11:15-11:30
11:30-12:00							11:30-12:00
	BASIC STATE-OF-THE-ART						
12:00-12:30	■ Main Plenary Karl Wilhelm von Kupffer basic state-of-the-art: The Immunology in the age of single cell genomics	power of ONE:					12:00-12:30
12:30-13:00					MEET TH	IE EXPERTS	12:30-13:00
13:00-13:30	INDUSTRY SYMPOSIA		ORAL ePOSTER	POSTER TOUR	transp	1 Assessing patients with NASH for lantation 2 Hepatitis B: Which new drugs are	13:00-13:30
						elopment and how do they work?	
13:30-14:00						IE EXPERTS	13:30-14:00
	SYMPOSIUM	PROS & CONS SESSION		THE BEST OF JHep		1 Bile duct strictures in PSC: vation or intervention?	
14:00-14:30	Lehar 3 Bioartificial livers, cell therapies and tissue engineering – The future of regenerative hepatology?     Main Plenary Patient prioritization for HCC treatment	Hepatology Arena Prolonged antibiotic	YI FUSION	Lehar 2 2015-2019 YOUNG	diseas	<b>2</b> Gut microbiota and liver e – where are the therapeutic tunities?	14:00-14:30
14:30-15:00	Hall C3 Multidisciplinary approaches to the management of NAFLD attention of NAFLD application with CEASL-ALEH SYMPOSIUM cirrhosis is harmful?		Strauss 3 Research opportunities for young	INVESTIGATORS SEMINAR Lehar 4 Hepatology	MEET THE EXPERTS  Stolz 1 Clinical management of		14:30-15:00
15:00-15:30	Strauss 1-2 Best practices and lessons learned from global viral hepatitis scale-up		investigators in billary diseases  FLASH ABSTRACT Pod 1 HBV and Pregnancy Pregnancy  polycystic liver disease Stotz 2 Weaning of immunosupp after liver transplantation		2 Weaning of immunosuppression	15:00-15:30	
15:30-16:00				ORAL ePOSTER		POSTER TOUR	15:30-16:00
16:00-16:30	SOLVE THE CASE	<u> </u>					16:00-16:30
16:30-17:00	Hepatology Arena Cholestasis and Autoimmune						16:30-17:00
17:00-17:30	SOLVE THE CASE	·	·				17:00-17:30
17:30-18:00	Hepatology Arena Advanced liver disease						17:30-18:00


# Sunday 14 April 2019


					1
07:30-08:00	BREAKFAST MORNING ROUNDS  Lehar 4 PSC: How is the surveillance? When do we need interventions (ERC), when and how to use UDC? When to consider liver transplantation?  Lehar 3 Cirrhosis and Portal hypertension: When TIPS, when and how Betablocker (propanolol or carvedilol?) and how to monitor?		<ul> <li>Lehar 1 Extrahepatic manifestation of HCV: Response to DAA and when to use immunosuppression?</li> <li>Lehar 2 Hepatitis B: When to start and when to stop Nuc therapy in HBeAg negative patients?</li> </ul>		
08:00-08:30					
08:30-09:00	PARALLEL SESSIONS  Strauss 3 Liver transplantation II	LIVER DISEASE AND THE COMMUNITY  Lehar 4 Part 1: EASL Policy	SOLVE THE CASE  Hepatology Arena Hepatological	MEET THE EXPERTS  Stolz 1 Portosinusoidal vascular	08:30-09:00
09:00-09:30	■ Strauss 1-2 NAFLD – Staging and prognosis	Statements – Alcohol and food	challenges	disease: What is there behind this new name?  Stolz 2 Haemochromatosis	09:00-09:30
09:30-10:00			MEET THE EXPERTS Stolz 2 Management of gastric varices Stolz 1 Management of non response to		09:30-10:00
10:00-10:30	Coffee b	reak 🔭			10:00-10:30
10:30-11:00	SYMPOSIA  Lehar 2 Preclinical models of NASH: in vitro, in vivo	LIVER DISEASE AND THE COMMUNITY  Lehar 4 Part 2: Hepatitis elimination	PROS & CONS SESSION  Hepatology Arena PBC patients with inadequate response to UDCA:	MEET THE EXPERTS Stolz 1 Acute liver failure Stolz 2 Pharmacotherapy in NAFLD	10:30-11:00
11:00-11:30	Strauss 3 Therapy of hepatitis C after DAA failure  Lehar 3 What do you need to know about Hepatitis E		obeticholic acid or bezafibrate?	- which endpoints to use in everyday practice?	11:00-11:30
11:30-12:00	Strauss 1-2 ILC 2019 WRAP UP SESSION				11:30-12:00
12:00-12:30					12:00-12:30
12:30-13:00					12:30-13:00

# **Industry programme overview**

	WEDNESDAY 10 APRIL 2019	THURSDAY 1	1 APRIL 2019	FRIDAY 12	APRIL 2019	SATURDAY 13 APRIL 2019	
07:30-08:00 08:00-08:30			anagement of nic non-viral liver gether we can nepatitis B virus  Extending the not or circlessi: long-nistration and beyond  Scaling up Testing Hepatitis with				08:00-08:30
				I			
12:30-13:00 13:00-13:30						SYMPOSIA  Hall C3 Gilead: Making a difference in diagnosing patients with advanced fibrosis due to NASH	12:30-13:00
13:30-14:00						Hall C1 MSD: Assessing Response in Advance Liver Cancer – Does Response Matter?	13:30-14:00
18:00-18:30							18:00-18:30
18:30-19:00	SYMPOSIA Hall C3 AbbVie: Transforming the HCV	SYMPOSIA Hepatology	MINI-WORKSHOPS  Lehar 3 Alexion:	SYMPOSIA  Main Plenary	MINI-WORKSHOP		18:30-19:00
19:00-19:30	Care Cascade: Making HCV Elimination a Reality  Strauss 3 Norgine: Preventing a domino effect in the management of hepatic encephalopathy  Strauss 1-2 Novo Nordisk: Understanding NASH as a metabolic disease	Arena Bristol- Myers Squilbb: Navigating patients through the evolving HCC treatment landscape  Strauss 3 Intercept: Advances in PBC Management:	My patient care vs restricted access to medicines  Lehar 4 Sequana Medical: Managing Ascites, improving Quality of Life	Gilead: Together we can Achieving HCV elimination through simplification  Hepatology Arena Intercept: NASH: What does the evidence tell	Perspectum Diagnostics: Introducing quantitative MRCP: Improving the clinical landscape for biliary disease		19:00-19:30
19:30-20:00		Management: Looking Beyord Biochemical Markers		evidence tell us?  Strauss 3 Shionogi: Procedural risk of bleeding - does the management of TCP in CLD patients make a difference? A debate			19:30-20:00

#### **Ground floor overview**





## Hall B – Exhibition, EASL community hub & poster area



LEGEND: MEETING ROOMS

#### **Exhibitors' list**

AASLD: American Association for the Study of Liver Diseases  AbbVie 140  Albutec GmbH Biotech Village  ALEH: Latin American Association for the Study of the Liver  Alexion Pharma GmbH 220  Allergan 250  Alnylam Pharmaceuticals 346  APASL: Asian Pacific Association for the Study of the Liver  APHC: PHC 2020 434  Apollo Endosurgery UK Ltd  Barcelona Liver Bioservices – BLB  BioPredictive 303  Biotest AG 143  Bristol-Myers Squibb Delegates Lounge  Cepheid 300  CymaBay Therapeutics 253  Diafir Biotech Village 2  Dr. Falk Pharma GmbH 200  Echosens 330	Company	<b>Booth Space</b>
Albutec GmbH Biotech Village  ALEH: Latin American Association for the Study of the Liver  Alexion Pharma GmbH 220  Allergan 250  Alnylam Pharmaceuticals 346  APASL: Asian Pacific Association for the Study of the Liver  APHC: PHC 2020 434  Apollo Endosurgery UK Ltd 302  Barcelona Liver Bioservices – BLB Biotech Village 1  Biotest AG 143  Bristol-Myers Squibb Delegates Lounge  Cepheid 300  CymaBay Therapeutics 253  Diafir Biotech Village 2  Dr. Falk Pharma GmbH 200	Association for the Study	420
ALEH: Latin American Association for the Study of the Liver  Alexion Pharma GmbH 220  Allergan 250  Alnylam Pharmaceuticals 346  APASL: Asian Pacific Association for the Study of the Liver  APHC: PHC 2020 434  Apollo Endosurgery UK Ltd 302  Barcelona Liver Bioservices – BLB Biotech Village 1  BioPredictive 303  Biotest AG 143  Bristol-Myers Squibb Delegates Lounge  Cepheid 300  CymaBay Therapeutics 253  Diafir Biotech Village 2  Dr. Falk Pharma GmbH 200	AbbVie	140
Association for the Study of the Liver  Alexion Pharma GmbH 220  Allergan 250  Alnylam Pharmaceuticals 346  APASL: Asian Pacific Association for the Study of the Liver  APHC: PHC 2020 434  Apollo Endosurgery UK Ltd 302  Barcelona Liver Bioservices – BLB Biotech Village 1  BioPredictive 303  Biotest AG 143  Bristol-Myers Squibb Delegates Lounge  Cepheid 300  CymaBay Therapeutics 253  Diafir Biotech Village 2  Dr. Falk Pharma GmbH 200	Albutec GmbH	Biotech Village
Allergan 250 Alnylam Pharmaceuticals 346 APASL: Asian Pacific Association for the Study of the Liver APHC: PHC 2020 434 Apollo Endosurgery UK Ltd Barcelona Liver Bioservices – BLB BioPredictive 303 Biotest AG 143 Bristol-Myers Squibb Delegates Lounge Cepheid 300 CymaBay Therapeutics 253 Diafir Biotech Village 2 Dr. Falk Pharma GmbH 200	Association for the Study	350
Alnylam Pharmaceuticals 346  APASL: Asian Pacific Association for the Study of the Liver  APHC: PHC 2020 434  Apollo Endosurgery UK Ltd 302  Barcelona Liver Bioservices – BLB Biotech Village 1  BioPredictive 303  Biotest AG 143  Bristol-Myers Squibb Delegates Lounge  Cepheid 300  CymaBay Therapeutics 253  Diafir Biotech Village 2  Dr. Falk Pharma GmbH 200	Alexion Pharma GmbH	220
APASL: Asian Pacific Association for the Study of the Liver  APHC: PHC 2020 434  Apollo Endosurgery UK Ltd 302  Barcelona Liver Bioservices – BLB Biotech Village 1  BioPredictive 303  Biotest AG 143  Bristol-Myers Squibb Delegates Lounge  Cepheid 300  CymaBay Therapeutics 253  Diafir Biotech Village 2  Dr. Falk Pharma GmbH 200	Allergan	250
Association for the Study of the Liver  APHC: PHC 2020 434  Apollo Endosurgery UK Ltd  Barcelona Liver Bioservices – BLB  BioPredictive 303  Biotest AG 143  Bristol-Myers Squibb Delegates Lounge  Cepheid 300  CymaBay Therapeutics 253  Diafir Biotech Village 2  Dr. Falk Pharma GmbH 200	Alnylam Pharmaceuticals	346
Apollo Endosurgery UK Ltd Barcelona Liver Bioservices – BLB BioPredictive 303 Biotest AG 143 Bristol-Myers Squibb Delegates Lounge Cepheid 300 CymaBay Therapeutics Dr. Falk Pharma GmbH 200	Association for the Study	432
UK Ltd  Barcelona Liver Bioservices – BLB  BioPredictive  303  Biotest AG  143  Bristol-Myers Squibb  Cepheid  300  CymaBay Therapeutics  Dr. Falk Pharma GmbH  200	APHC: PHC 2020	434
Bioservices – BLB  BioPredictive  303  Biotest AG  143  Bristol-Myers Squibb  Cepheid  300  CymaBay Therapeutics  253  Diafir  Biotech Village 2  Dr. Falk Pharma GmbH  Biotech Village 2		302
Biotest AG 143  Bristol-Myers Squibb Delegates Lounge Cepheid 300  CymaBay Therapeutics 253  Diafir Biotech Village 2  Dr. Falk Pharma GmbH 200		Biotech Village 1
Bristol-Myers Squibb Delegates Lounge Cepheid 300 CymaBay Therapeutics 253 Diafir Biotech Village 2 Dr. Falk Pharma GmbH 200	BioPredictive	303
Cepheid         300           CymaBay Therapeutics         253           Diafir         Biotech Village 2           Dr. Falk Pharma GmbH         200	Biotest AG	143
CymaBay Therapeutics 253 Diafir Biotech Village 2 Dr. Falk Pharma GmbH 200	Bristol-Myers Squibb	Delegates Lounge
Diafir Biotech Village 2  Dr. Falk Pharma GmbH 200	Cepheid	300
Dr. Falk Pharma GmbH 200	CymaBay Therapeutics	253
	Diafir	Biotech Village 2
Echosens 330	Dr. Falk Pharma GmbH	200
	Echosens	330


Company	<b>Booth Space</b>
EFSUMB: European Federation of Societies for Ultrasound	349
Eiger BioPharmaceuticals, Inc.	109
ELPA: European Liver Patients' Association	401, 410
Enanta Pharmaceuticals	251
Endra Life Sciences	114
FIANOSTICS GmbH	455
Fujirebio Europe NV	336
Genedrive Diagnostics Ltd.	433
Genfit	240
Gilead Sciences Europe Ltd	360, 370, 380
GMP Orphan Deutschland GmbH	435
Gore & Associates	320
Grifols	332
Gubra ApS	431
Helena Biosciences	260
Hep C Action Aotearoa	344
High Point Clinical Trials Center	443
Humedics	155
ICE-HBV: International Coalition to Eliminate HBV	351

Company	<b>Booth Space</b>
INHSU: International Network on Hepatitis in Substance Users	343
Intercept	160, 352
Ipsen	400
Liver Systems Medicine (LiSyM) Network	Biotech Village
Liverpool Drug Interactions	340
MSD	230
MYR Pharma	450
Norgine	150
Novartis Pharma AG	210
Novo Nordisk A/S	102
OraSure Technologies	163
Perspectum Diagnostics	130
Philips Healthcare	115
PhoenixBio	430
Promethera Biosciences	Biotech Village 6
ProSciento	451
Research Diets, Inc.	156
Resoundant Inc.	270
Sanyal Biotechnology LLC	Biotech Village 3
Sequana Medical NV	Biotech Village 4
Shionogi Limited	338
Siemens Healthcare GmbH	161

	B 11 0
Company	Booth Space
SuperSonic Imagine	110
TASL: Taiwan Association for the Study of the Liver	339
The Cochrane Hepato-Biliary Group	337
United European Gastroenterology (UEG)	345
VIDC: Vancouver Infectious Diseases Centre	334
Virology Education	348
VLVbio	Biotech Village 5
WGO: World Gastroenterology Organisation	342
WHA: World Hepatitis Alliance	153
Wisepress	440
Zero Gravity Skin	442

#### Hall B – Poster area overview

























441-450 451-460 461-470 471-480







